A Novel Bispecific T-Cell Engager (BiTE) Targeting CD22 and CD3 Has Both In Vitro and In Vivo Activity and Synergizes With Blinatumomab in an Acute Lymphoblastic Leukemia (ALL) Tumor Model

By
Jamie Kang
-
0
173
Scientists reported the development of a new BiTE with cytotoxic activity against CD22+ cells which could represent an alternate or complementary therapeutic option for B cell malignancies.
[Cancer Immunology Immunotherapy]
Full Article